Neutrophil membrane-coated nanoparticles for targeted therapy
Source abstract
Abstract
Traditional drug delivery systems often face problems such as low drug accumulation at the target site, rapid clearance in the body, and potential damage to healthy tissues. Under such circumstances, nanoparticle drug delivery systems have been developed. Although they have certain advantages, they still struggle to achieve efficient and specific targeting and may exhibit cytotoxicity. In contrast, neutrophil membrane-coated nanoparticles (NM-NPs) inherit the natural cell surface proteins and ligands of neutrophils, possessing numerous advantages such as low immunogenicity, immune evasion, and the ability to achieve precise targeting, thus showing great potential. This review is the first article to comprehensively summarize the application of neutrophil membrane-coated nanoparticles in targeted therapy. It mainly focuses on the pathophysiological role of neutrophils, the advantages of neutrophil membrane coating, the selection and preparation of nanoparticle cores, the targeting mechanism of neutrophil membrane-coated nanoparticles, the types of nano-drugs for targeted delivery, their application in disease treatment, and discussions on related safety and toxicology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Neutrophil, Myeloperoxidase and Oxidative Mechanisms · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, et al. Paul Ehrlich (1854–1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun. 2016;8(2):111–20.10.1159/000443526 ↗
2. Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, et al. Targeting regulated cell death: apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity. J Transl Intern Med. 2025;13(1):10–32.10.1515/jtim-2025-0004 ↗
3. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021. https://doi.org/10.3390/molecules26195905.10.3390/molecules26195905 ↗
4. Guo Y, Huang J, Lin M, Yin Q, Zhang T, Guo Z, et al. Nano particle loaded EZH2 inhibitors: increased efficiency and reduced toxicity for malignant solid tumors. J Transl Intern Med. 2025;13(2):156–69.10.1515/jtim-2025-0020 ↗
5. Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6(12):eaaw6071.10.1126/sciadv.aaw6071 ↗
6. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1):26–49.10.1002/smll.200700595 ↗
7. Wu M, Le W, Mei T, Wang Y, Chen B, Liu Z, et al. Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy. Int J Nanomed. 2019;14:4431–48.10.2147/IJN.S200284 ↗
8. Yang X, Chen M, Weng C, Zhuge D, Jin F, Xiao Y, et al. Red blood cell membrane-coated nanoparticles enable incompatible blood transfusions. Adv Sci. 2024;11(29):e2310230.10.1002/advs.202310230 ↗
9. Kunde SS, Wairkar S. Platelet membrane camouflaged nanoparticles: biomimetic architecture for targeted therapy. Int J Pharm. 2021;598:120395.10.1016/j.ijpharm.2021.120395 ↗
10. Wang C, Li C, Zhang R, Huang L. Macrophage membrane-coated nanoparticles for the treatment of infectious diseases. Biomed Mater. 2024. https://doi.org/10.1088/1748-605X/ad4aaa.10.1088/1748-605X/ad4aaa ↗
11. Li W, Liu C, Wang S, Liu N. Neutrophil membrane biomimetic delivery system (Ptdser-NM-Lipo/Fer-1) designed for targeting atherosclerosis therapy. IET Nanobiotechnol. 2023;17(4):387–95.10.1049/nbt2.12137 ↗
12. Li TX, Yang YY, Zong JB, Li M, Fu XX, Jiang XX, et al. Activated neutrophil membrane-coated tRF-Gly-CCC nanoparticles for the treatment of aortic dissection/aneurysm. J Control Release. 2025;378:334–49.10.1016/j.jconrel.2024.12.015 ↗
13. Zhang Q, Hu C, Feng J, Long H, Wang Y, Wang P, et al. Anti-inflammatory mechanisms of neutrophil membrane-coated nanoparticles without drug loading. J Control Release. 2024;369:12–24.10.1016/j.jconrel.2024.03.030 ↗
14. Liu Y, He M, Yuan Y, Nie C, Wei K, Zhang T, et al. Neutrophil-membrane-coated biomineralized metal-organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing. ACS Nano. 2023;17(8):7721–32.10.1021/acsnano.3c00288 ↗
15. Tang Y, Shen Y, Zang X, Wu P, Li L, Qian H, et al. Neutrophil membrane engineered human umbilical cord MSC-derived sEVs enhance anti-tumor efficacy for gastric cancer via delivering pentraxin 3. J Control Release. 2025;383:113828.10.1016/j.jconrel.2025.113828 ↗
16. Yang N, Li M, Wu L, Song Y, Yu S, Wan Y, et al. Peptide-anchored neutrophil membrane-coated biomimetic nanodrug for targeted treatment of rheumatoid arthritis. J Nanobiotechnol. 2023;21(1):13.10.1186/s12951-023-01773-x ↗
17. Dahl R, Walsh JC, Lancki D, Laslo P, Iyer SR, Singh H, et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol. 2003;4(10):1029–36.10.1038/ni973 ↗
18. Vafadarnejad E, Rizzo G, Krampert L, Arampatzi P, Arias-Loza AP, Nazzal Y, et al. Dynamics of cardiac neutrophil diversity in murine myocardial infarction. Circ Res. 2020;127(9):e232–49.10.1161/CIRCRESAHA.120.317200 ↗
19. Aluri J, Cooper MA, Schuettpelz LG. Toll-like receptor signaling in the establishment and function of the immune system. Cells. 2021. https://doi.org/10.3390/cells10061374.10.3390/cells10061374 ↗
20. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459–89.10.1146/annurev-immunol-020711-074942 ↗
21. Lyck R, Enzmann G. The physiological roles of ICAM-1 and ICAM-2 in neutrophil migration into tissues. Curr Opin Hematol. 2015;22(1):53–9.10.1097/MOH.0000000000000103 ↗
22. Petri B, Sanz MJ. Neutrophil chemotaxis. Cell Tissue Res. 2018;371(3):425–36.10.1007/s00441-017-2776-8 ↗
23. Lim JJ, Grinstein S, Roth Z. Diversity and versatility of phagocytosis: roles in innate immunity, tissue remodeling, and homeostasis. Front Cell Infect Microbiol. 2017;7:191.10.3389/fcimb.2017.00191 ↗
24. Kosyreva AM, Miroshnichenko EA, Makarova OV. The role of neutrophils in the mechanisms of sepsis. Russ J Arch Pathol. 2024;86(6):82–91.10.17116/patol20248606182 ↗
25. Herre M, Cedervall J, Mackman N, Olsson AK. Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. Physiol Rev. 2023;103(1):277–312.10.1152/physrev.00062.2021 ↗
26. Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood. 2019;133(20):2178–85.10.1182/blood-2018-11-844530 ↗
27. Loh W, Vermeren S. Anti-inflammatory neutrophil functions in the resolution of inflammation and tissue repair. Cells. 2022. https://doi.org/10.3390/cells11244076.10.3390/cells11244076 ↗
28. Hsu AY, Huang Q, Pi X, Fu J, Raghunathan K, Ghimire L, et al. Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution. Cell. 2025;188(6):1623-41.e26.10.1016/j.cell.2025.01.021 ↗
29. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95.10.1172/JCI59643 ↗
30. Lu YZ, Nayer B, Singh SK, Alshoubaki YK, Yuan E, Park AJ, et al. CGRP sensory neurons promote tissue healing via neutrophils and macrophages. Nature. 2024;628(8008):604–11.10.1038/s41586-024-07237-y ↗
31. Campbell EL. Hypoxia-recruited angiogenic neutrophils. Blood. 2015;126(17):1972–3.10.1182/blood-2015-09-666578 ↗
32. Jain N, Shahrukh S, Famta P, Shah S, Vambhurkar G, Khatri DK, et al. Immune cell-camouflaged surface-engineered nanotherapeutics for cancer management. Acta Biomater. 2023;155:57–79.10.1016/j.actbio.2022.11.001 ↗
33. Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20(1):33–48.10.1038/s41571-022-00699-x ↗
34. Marchi LF, Sesti-Costa R, Chedraoui-Silva S, Mantovani B. Comparison of four methods for the isolation of murine blood neutrophils with respect to the release of reactive oxygen and nitrogen species and the expression of immunological receptors. Comp Clin Pathol. 2014;23(5):1469–76.10.1007/s00580-013-1808-3 ↗
35. Boxio R, Bossenmeyer-Pourié C, Steinckwich N, Dournon C, Nüsse O. Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol. 2004;75(4):604–11.10.1189/jlb.0703340 ↗
36. Wishart AL, Swamydas M, Lionakis MS. Isolation of mouse neutrophils. Curr Protoc. 2023;3(9):e879.10.1002/cpz1.879 ↗
37. Oh H, Siano B, Diamond S. Neutrophil isolation protocol: 1940–087X; 2008. e745 p.10.3791/745-v ↗
38. Boone CW, Ford LE, Bond HE, Stuart DC, Lorenz D. Isolation of plasma membrane fragments from HeLa cells. J Cell Biol. 1969;41(2):378–92.10.1083/jcb.41.2.378 ↗
39. Li H, Sun D, Zhao Z, Fang J, Li M, Lv C, et al. Neutrophil membrane-derived nanoparticles protect traumatic brain injury via inhibiting calcium overload and scavenging ROS. J Nanobiotechnol. 2024;22(1):477.10.1186/s12951-024-02753-5 ↗
40. Gao J, Wang S, Wang Z. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials. 2017;135:62–73.10.1016/j.biomaterials.2017.05.003 ↗
41. Phatale V, Famta P, Srinivasarao DA, Vambhurkar G, Jain N, Pandey G, et al. Neutrophil membrane-based nanotherapeutics: propitious paradigm shift in the management of cancer. Life Sci. 2023;331:122021.10.1016/j.lfs.2023.122021 ↗
42. Zhao Q, Jiang D, Sun X, Mo Q, Chen S, Chen W, et al. Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. J Nanobiotechnol. 2021;19(1):179.10.1186/s12951-021-00922-4 ↗
43. Zhang N, Zhang T, Feng J, Shang J, Zhang B, Dong Q, et al. Application of therapeutical nanoparticles with neutrophil membrane camouflaging for inflammatory plaques targeting against atherosclerosis. Mater Today Bio. 2025;30:101397.10.1016/j.mtbio.2024.101397 ↗
44. Rao Z, Tang Y, Zhu J, Lu Z, Chen Z, Wang J, et al. Enhanced FGF21 delivery via neutrophil-membrane-coated nanoparticles improves therapeutic efficacy for myocardial ischemia-reperfusion injury. Nanomaterials. 2025. https://doi.org/10.3390/nano15050346.10.3390/nano15050346 ↗
45. Wang Y, Yan J, Wen N, Xiong H, Cai S, He Q, et al. Metal-organic frameworks for stimuli-responsive drug delivery. Biomaterials. 2020;230:119619.10.1016/j.biomaterials.2019.119619 ↗
46. Ejsmont A, Warowicka A, Broniarczyk J, Goscianska J. The synergistic effect of Cu-MOF nanoparticles and immunomodulatory agent on SARS-CoV-2 inhibition. Chem Commun. 2023;59(33):4907–10.10.1039/D3CC00894K ↗
47. Furukawa H, Cordova KE, O’Keeffe M, Yaghi OM. The chemistry and applications of metal-organic frameworks. Science. 2013;341(6149):1230444.10.1126/science.1230444 ↗
48. Gao L, Zhuang J, Nie L, Zhang J, Zhang Y, Gu N, et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat Nanotechnol. 2007;2(9):577–83.10.1038/nnano.2007.260 ↗
49. Ma S, Zhan S, Jia Y, Zhou Q. Superior antibacterial activity of Fe3O4-TiO2 nanosheets under solar light. ACS Appl Mater Interfaces. 2015;7(39):21875–83.10.1021/acsami.5b06264 ↗
50. Pang F, He M, Ge J. Controlled synthesis of Fe3O4/ZIF-8 nanoparticles for magnetically separable nanocatalysts. Chem Eur J. 2015;21(18):6879–87.10.1002/chem.201405921 ↗
51. Yang X, Liu J, He H, Zhou L, Gong C, Wang X, et al. SiO2 nanoparticles induce cytotoxicity and protein expression alteration in HaCaT cells. Part Fibre Toxicol. 2010;7:1.10.1186/1743-8977-7-1 ↗
52. Heuer-Jungemann A, Feliu N, Bakaimi I, Hamaly M, Alkilany A, Chakraborty I, et al. The role of ligands in the chemical synthesis and applications of inorganic nanoparticles. Chem Rev. 2019;119(8):4819–80.10.1021/acs.chemrev.8b00733 ↗
53. Porrang S, Rahemi N, Davaran S, Mahdavi M, Hassanzadeh B. Synthesis of temperature/pH dual-responsive mesoporous silica nanoparticles by surface modification and radical polymerization for anti-cancer drug delivery. Colloids Surf A Physicochem Eng Asp. 2021;623:126719.10.1016/j.colsurfa.2021.126719 ↗
54. Rocha CV, Gonçalves V, da Silva MC, Bañobre-López M, Gallo J. PLGA-based composites for various biomedical applications. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23042034.10.3390/ijms23042034 ↗
55. Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y, et al. PLGA-based nanoparticles in cancer treatment. Front Pharmacol. 2018;9:1260.10.3389/fphar.2018.01260 ↗
56. Sharma S, Parmar A, Kori S, Sandhir R. PLGA-based nanoparticles: a new paradigm in biomedical applications. TrAC Trends Anal Chem. 2016;80:30–40.10.1016/j.trac.2015.06.014 ↗
57. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325–41.10.1586/erm.09.15 ↗
58. Jafernik K, Ładniak A, Blicharska E, Czarnek K, Ekiert H, Wiącek AE, et al. Chitosan-based nanoparticles as effective drug delivery systems-a review. Molecules. 2023. https://doi.org/10.3390/molecules28041963.10.3390/molecules28041963 ↗
59. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28.10.1016/j.jconrel.2004.08.010 ↗
60. Garg U, Chauhan S, Nagaich U, Jain N. Current advances in chitosan nanoparticles based drug delivery and targeting. Adv Pharm Bull. 2019;9(2):195–204.10.15171/apb.2019.023 ↗
61. Sreekumar S, Goycoolea FM, Moerschbacher BM, Rivera-Rodriguez GR. Parameters influencing the size of chitosan-TPP nano- and microparticles. Sci Rep. 2018;8(1):4695.10.1038/s41598-018-23064-4 ↗
62. Yi Y, Wang Y, Liu H. Preparation of new crosslinked chitosan with crown ether and their adsorption for silver ion for antibacterial activities. Carbohydr Polym. 2003;53(4):425–30.10.1016/S0144-8617(03)00104-8 ↗
63. Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 2020. https://doi.org/10.3390/molecules25235672.10.3390/molecules25235672 ↗
64. Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154–155:102–22.10.1016/j.addr.2020.07.002 ↗
65. Khadke S, Roces CB, Cameron A, Devitt A, Perrie Y. Formulation and manufacturing of lymphatic targeting liposomes using microfluidics. J Control Release. 2019;307:211–20.10.1016/j.jconrel.2019.06.002 ↗
66. Chen G, Li D, Jin Y, Zhang W, Teng L, Bunt C, et al. Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechin. Drug Dev Ind Pharm. 2014;40(2):260–5.10.3109/03639045.2012.756512 ↗
67. Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, et al. Cathepsin G controls arterial but not venular myeloid cell recruitment. Circulation. 2016;134(16):1176–88.10.1161/CIRCULATIONAHA.116.024790 ↗
68. Anzai A, Shimoda M, Endo J, Kohno T, Katsumata Y, Matsuhashi T, et al. Adventitial CXCL1/G-CSF expression in response to acute aortic dissection triggers local neutrophil recruitment and activation leading to aortic rupture. Circ Res. 2015;116(4):612–23.10.1161/CIRCRESAHA.116.304918 ↗
69. Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17(6):327–40.10.1038/s41569-019-0326-7 ↗
70. Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24–31.10.1016/j.ctrv.2017.08.004 ↗
71. Matsushima K, Yang D, Oppenheim JJ. Interleukin-8: an evolving chemokine. Cytokine. 2022;153:155828.10.1016/j.cyto.2022.155828 ↗
72. Stadtmann A, Zarbock A. CXCR2: from bench to bedside. Front Immunol. 2012;3:263.10.3389/fimmu.2012.00263 ↗
73. Sai J, Fan GH, Wang D, Richmond A. The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. J Cell Sci. 2004;117(Pt 23):5489–96.10.1242/jcs.01398 ↗
74. Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther. 2021;6(1):94.10.1038/s41392-020-00443-w ↗
75. Kaltenmeier C, Wang R, Popp B, Geller D, Tohme S, Yazdani HO. Role of immuno-inflammatory signals in liver ischemia-reperfusion injury. Cells. 2022. https://doi.org/10.3390/cells11142222.10.3390/cells11142222 ↗
76. Bruntz RC, Taylor HE, Lindsley CW, Brown HA. Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem. 2014;289(2):600–16.10.1074/jbc.M113.532978 ↗
77. He X, Li Y, Deng B, Lin A, Zhang G, Ma M, et al. The PI3K/AKT signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: mechanisms and therapeutic opportunities. Cell Prolif. 2022;55(9):e13275.10.1111/cpr.13275 ↗
78. Dong H, Zhang X, Dai X, Lu S, Gui B, Jin W, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J Neuroinflamm. 2014;11:140.10.1186/s12974-014-0140-4 ↗
79. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology. 2013;140(2):179–90.10.1111/imm.12126 ↗
80. Catz SD, McLeish KR. Therapeutic targeting of neutrophil exocytosis. J Leukoc Biol. 2020;107(3):393–408.10.1002/JLB.3RI0120-645R ↗
81. Cappenberg A, Kardell M, Zarbock A. Selectin-mediated signaling-shedding light on the regulation of integrin activity in neutrophils. Cells. 2022. https://doi.org/10.3390/cells11081310.10.3390/cells11081310 ↗
82. Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011. https://doi.org/10.1101/cshperspect.a004994.10.1101/cshperspect.a004994 ↗
83. Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, et al. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res. 2022;24(1):99.10.1186/s13058-022-01596-y ↗
84. Su Y, Zhu K, Wang J, Liu B, Chang Y, Chang D, et al. Advancing Src kinase inhibition: from structural design to therapeutic innovation—a comprehensive review. Eur J Med Chem. 2025;287:117369.10.1016/j.ejmech.2025.117369 ↗
85. Sun HL, Ma QY, Bian HG, Meng XM, Jin J. Novel insight on GRP/GRPR axis in diseases. Biomed Pharmacother. 2023;161:114497.10.1016/j.biopha.2023.114497 ↗
86. Mosaddeghzadeh N, Ahmadian MR. The RHO family GTPases: mechanisms of regulation and signaling. Cells. 2021. https://doi.org/10.3390/cells10071831.10.3390/cells10071831 ↗
87. Vallés PG, Gil Lorenzo AF, Garcia RD, Cacciamani V, Benardon ME, Costantino VV. Toll-like receptor 4 in acute kidney injury. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24021415.10.3390/ijms24021415 ↗
88. Chen SN, Tan Y, Xiao XC, Li Q, Wu Q, Peng YY, et al. Deletion of TLR4 attenuates lipopolysaccharide-induced acute liver injury by inhibiting inflammation and apoptosis. Acta Pharmacol Sin. 2021;42(10):1610–9.10.1038/s41401-020-00597-x ↗
89. Płóciennikowska A, Hromada-Judycka A, Borzęcka K, Kwiatkowska K. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557–81.10.1007/s00018-014-1762-5 ↗
90. Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021;78(4):1233–61.10.1007/s00018-020-03656-y ↗
91. Tang J, Xu L, Zeng Y, Gong F. Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway. Int Immunopharmacol. 2021;91:107272.10.1016/j.intimp.2020.107272 ↗
92. Pallett LJ, Swadling L, Diniz M, Maini AA, Schwabenland M, Gasull AD, et al. Tissue CD14(+)CD8(+) T cells reprogrammed by myeloid cells and modulated by LPS. Nature. 2023;614(7947):334–42.10.1038/s41586-022-05645-6 ↗
93. Bernard A, Eggstein C, Tang L, Keller M, Körner A, Mirakaj V, et al. Plexin C1 influences immune response to intracellular LPS and survival in murine sepsis. J Biomed Sci. 2024;31(1):82.10.1186/s12929-024-01074-x ↗
94. Cao L, Du M, Cai M, Feng Y, Miao J, Sun J, et al. Neutrophil membrane-coated nanoparticles for targeted delivery of toll-like receptor 4 siRNA ameliorate LPS-induced acute lung injury. Int J Pharm. 2025;668:124960.10.1016/j.ijpharm.2024.124960 ↗
95. Lu D, Li W, Tan J, Li Y, Mao W, Zheng Y, et al. STING agonist delivered by neutrophil membrane-coated gold nanoparticles exerts synergistic tumor inhibition with radiotherapy. ACS Appl Mater Interfaces. 2024;16(40):53474–88.10.1021/acsami.4c09825 ↗
96. Jiang Y, Jiang R, Xia Z, Guo M, Fu Y, Wang X, et al. Engineered neutrophil membrane-camouflaged nanocomplexes for targeted siRNA delivery against myocardial ischemia reperfusion injury. J Nanobiotechnol. 2025;23(1):134.10.1186/s12951-025-03172-w ↗
97. Wang Z, Qi F, Luo H, Xu G, Wang D. Inflammatory microenvironment of skin wounds. Front Immunol. 2022;13:789274.10.3389/fimmu.2022.789274 ↗
98. Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–61.10.1038/s41577-020-0406-2 ↗
99. Zhang G, Ma L, Bai L, Li M, Guo T, Tian B, et al. Inflammatory microenvironment-targeted nanotherapies. J Control Release. 2021;334:114–26.10.1016/j.jconrel.2021.04.018 ↗
100. Sadeqi Nezhad M. Poly (beta-amino ester) as an in vivo nanocarrier for therapeutic nucleic acids. Biotechnol Bioeng. 2023;120(1):95–113.10.1002/bit.28269 ↗